In:
JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY, Journal of Bone Marrow Transplantation and Cellular Therapy, Vol. 2, No. 4 ( 2021-11-30), p. 127-
Abstract:
MDS in children is a rare group of hematopoietic stem cell clonal disorder. Allogeneic HSCT is the only curative treatment. HLA typing and the search for a compatible donor must be carried out upon diagnosis, for all patients. However, patients with refractory cytopenia of childhood without an unfavorable karyotype can keep the disease stable for a long time. Thus, in the absence of transfusion dependence or severe neutropenia, a careful observation strategy without treatment is recommended. The treatment of children diagnosed with MDS with excess blasts remains a major challenge. Allogeneic HSCT is the only curative treatment, although the data published in the literature generally include a small number of patients, heterogeneously transplanted. For children with MDS secondary to therapy, despite HSCT, the evolution is generally unfavorable.
Type of Medium:
Online Resource
ISSN:
2675-374X
DOI:
10.46765/2675-374X.2021v2n4
DOI:
10.46765/2675-374X.2021v2n4p127
Language:
Unknown
Publisher:
Journal of Bone Marrow Transplantation and Cellular Therapy
Publication Date:
2021
Permalink